{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:44:02Z","timestamp":1793411042651,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Medical Scientific Research Foundation of Guangdong Province, China","award":["2014246"],"award-info":[{"award-number":["2014246"]}]},{"name":"Sister Institution Network Fund of the University of Texas MD Anderson Cancer Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin J Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40880-017-0212-9","type":"journal-article","created":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T01:25:44Z","timestamp":1494379544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["CD30 expression in extranodal natural killer\/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China"],"prefix":"10.1186","volume":"36","author":[{"given":"Yanfen","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,10]]},"reference":[{"key":"212_CR1","volume-title":"WHO Classification of tumors of hematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO Classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.","edition":"4"},{"issue":"25","key":"212_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. doi:\n                    10.1200\/JCO.2008.16.4558\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"20","key":"212_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. doi:\n                    10.1182\/blood-2016-01-643569\n                    \n                  .","journal-title":"Blood"},{"issue":"11","key":"212_CR4","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137. doi:\n                    10.1093\/annonc\/mdu443\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"212_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40880-016-0096-0","volume":"35","author":"SQ Niu","year":"2016","unstructured":"Niu SQ, Yang Y, Li YY, Wen G, Wang L, Li ZM, et al. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer\/T cell lymphoma. Chin J Cancer. 2016;35:34. doi:\n                    10.1186\/s40880-016-0096-0\n                    \n                  .","journal-title":"Chin J Cancer"},{"issue":"9","key":"212_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2147\/DDDT.S82007","volume":"2015","author":"R Chen","year":"2015","unstructured":"Chen R, Chen B. Brentuximab vedotin for relapsed or refractory Hodgkin\u2019s lymphoma. Drug Des Devel Ther. 2015;2015(9):1729\u201333. doi:\n                    10.2147\/DDDT.S82007.eCollection\n                    \n                  .","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"212_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40259-013-0068-8","volume":"28","author":"T Schirrmann","year":"2014","unstructured":"Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S. CD30 as a therapeutic target for lymphoma. BioDrugs. 2014;28(2):181\u2013209. doi:\n                    10.1007\/s40259-013-0068-8\n                    \n                  .","journal-title":"BioDrugs"},{"issue":"8","key":"212_CR8","first-page":"508","volume":"43","author":"Y Feng","year":"2014","unstructured":"Feng Y, Fu J, Yan S, Ling Y, Huang Y, Cai M, et al. Analysis of mature T-cell and NK-cell lymphoma with CD30 expression based on latest WHO classification. Zhonghua Bing Li Xue Za Zhi. 2014;43(8):508\u201311 (in Chinese).","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"14","key":"212_CR9","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715\u201324. doi:\n                    10.1182\/blood-2012-10-461848\n                    \n                  .","journal-title":"Blood"},{"issue":"3","key":"212_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1309\/AJCPWKJ3GPFRT7GA","volume":"138","author":"YL Ren","year":"2012","unstructured":"Ren YL, Nong L, Zhang S, Zhao J, Zhang XM, Li T. Analysis of 142 northern Chinese patients with peripheral T\/NK-Cell lymphomas: subtype distribution, clinicopathologic features, and prognosis. Am J Clin Pathol. 2012;138(3):435\u201347. doi:\n                    10.1309\/AJCPWKJ3GPFRT7GA\n                    \n                  .","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"212_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hon.853","volume":"26","author":"N Niitsu","year":"2008","unstructured":"Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol. 2008;26(3):152\u20138. doi:\n                    10.1002\/hon.853\n                    \n                  .","journal-title":"Hematol Oncol"},{"issue":"9","key":"212_CR12","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","volume":"17","author":"Z Li","year":"2016","unstructured":"Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016;17(9):1240\u20137. doi:\n                    10.1016\/S1470-2045(16)30148-6\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"14","key":"212_CR13","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1074\/jbc.M608817200","volume":"282","author":"CW Wright","year":"2007","unstructured":"Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-\u03baB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007;282(14):10252\u201362.","journal-title":"J Biol Chem"},{"issue":"6","key":"212_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2014.974048","volume":"56","author":"WY Kim","year":"2015","unstructured":"Kim WY, Nam SJ, Kim S, Kim TM, Heo DS, Kim CW, et al. Prognostic implications of CD30 expression in extranodal natural killer\/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2015;56(6):1178\u201386. doi:\n                    10.3109\/10428194.2014.974048\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"212_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/106689690401200410","volume":"12","author":"TT Kuo","year":"2004","unstructured":"Kuo TT, Shih LY, Tsang NM. Nasal NK\/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol. 2004;12(4):375\u201387.","journal-title":"Int J Surg Pathol"},{"issue":"9","key":"212_CR16","first-page":"939","volume":"5","author":"J Hong","year":"2012","unstructured":"Hong J, Park S, Baek HL, Jung JH, Kang IG, Sym SJ, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK\/T-cell lymphoma nasal type. Int J Clin Exp Pathol. 2012;5(9):939\u201347.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"212_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1179\/1607845413Y.0000000097","volume":"19","author":"Z Lin","year":"2014","unstructured":"Lin Z, Chen B, Xu X, Wang X, Lin G. Analysis of clinical characteristics of 516 patients with non-Hodgkin\u2019s lymphoma in Shanghai area. Hematology. 2014;19(2):99\u2013106.","journal-title":"Hematology"},{"issue":"4","key":"212_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5501\/wjv.v3.i4.22","volume":"3","author":"M Cao","year":"2014","unstructured":"Cao M, Wang Q, Lingel A, Zhang L. Nuclear factor \u03baB represses the expression of latent membrane protein 1 in Epstein-Barr virus transformed cells. World J Virol. 2014;3(4):22\u20139.","journal-title":"World J Virol"},{"issue":"8","key":"212_CR19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","volume":"98","author":"B Bisig","year":"2013","unstructured":"Bisig B, de Reyni\u00e8s A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica. 2013;98(8):1250\u20138.","journal-title":"Haematologica"},{"issue":"34","key":"212_CR20","doi-asserted-by":"publisher","first-page":"8718","DOI":"10.1016\/j.biomaterials.2013.07.068","volume":"34","author":"O Molavi","year":"2013","unstructured":"Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, et al. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials. 2013;34(34):8718\u201325. doi:\n                    10.1016\/j.biomaterials.2013.07.068\n                    \n                  .","journal-title":"Biomaterials"},{"issue":"9","key":"212_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5732\/cjc.012.10221","volume":"32","author":"ZG Cao","year":"2013","unstructured":"Cao ZG, Zhou HW, Peng CJ, Liu M, Du Y, Yang QM. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin. Chin J Cancer. 2013;32(9):520\u20133. doi:\n                    10.5732\/cjc.012.10221\n                    \n                  .","journal-title":"Chin J Cancer"},{"issue":"20","key":"212_CR22","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095\u2013100. doi:\n                    10.1182\/blood-2013-12-542142\n                    \n                  .","journal-title":"Blood"},{"issue":"4","key":"212_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","volume":"50","author":"HK Kim","year":"2015","unstructured":"Kim HK, Moon SM, Moon JH, Park JE, Byeon S, et al. Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin. Blood Res. 2015;50(4):254\u20136. doi:\n                    10.5045\/br.2015.50.4.254\n                    \n                  .","journal-title":"Blood Res"},{"key":"212_CR24","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1200\/JCO.2015.61.9486","volume":"33","author":"HM Prince","year":"2015","unstructured":"Prince HM. CD30 as a target for the treatment of cutaneous T-Cell lymphoma. J Clin Oncol. 2015;33:3691\u20136. doi:\n                    10.1200\/JCO.2015.61.9486\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"212_CR25","unstructured":"Jagadeesh D. A phase II study of single agent brentuximab vedotin in relapsed\/refractory CD30 low (<10%) mature T cell lymphoma (TCL). case comprehensive cancer center. \n                    https:\/\/Clinicaltrials.gov\/show\/NCT02588651\n                    \n                  . Accessed 28 Sept 2016."},{"key":"212_CR26","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1038\/emm.2014.102","volume":"47","author":"Eric Tse","year":"2015","unstructured":"Tse Eric, Kwong Yok-Lam. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Exp Mol Med. 2015;47:e136. doi:\n                    10.1038\/emm.2014.102\n                    \n                  .","journal-title":"Exp Mol Med"},{"issue":"1","key":"212_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","volume":"104","author":"WY Au","year":"2004","unstructured":"Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243\u20139.","journal-title":"Blood"},{"key":"212_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1749-6632.2001.tb03865.x","volume":"945","author":"YM Lo","year":"2001","unstructured":"Lo YM. Quantitative analysis of Epstein-Barr virus DNA in plasma and serum: applications to tumor detection and monitoring. Ann NY Acad Sci. 2001;945:68\u201372.","journal-title":"Ann NY Acad Sci"}],"container-title":["Chinese Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-017-0212-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T21:01:09Z","timestamp":1526158869000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancercommun.biomedcentral.com\/articles\/10.1186\/s40880-017-0212-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s40880-017-0212-9","relation":{},"ISSN":["1944-446X"],"issn-type":[{"value":"1944-446X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,10]]},"article-number":"43"}}